#United States #Immunotherapy #Compugen #Miami Beach #CGEN

Compugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare Conference

Compugen Ltd., a prominent clinical-stage cancer immunotherapy company, is set to engage in a fireside chat at the much-anticipated 2025 Leerink Partners Global Healthcare Conference. This event will take place on March 11, 2025, at 8:00 AM ET, nestled in the vibrant setting of Miami Beach, Florida.

As a leader in computational target discovery, Compugen is making waves in the healthcare sector, especially in the realm of cancer treatment innovation. The management's participation in this significant event underscores both their commitment and contributions to advancing cancer immunotherapy research. The insights shared during this chat will provide a deeper understanding of Compugen's work and their pioneering projects aimed at revolutionizing the treatment of cancer.

Those interested in attending can look forward to a live webcast, which will be available on the Investor Relations section of Compugen's official website at www.cgen.com. Following the live event, a replay will also be accessible, allowing for further engagement with the content shared.

About Compugen

Compugen is at the forefront of therapeutic discovery and development, distinguished by its innovative predictive computational discovery platform, known as Unigen™. This platform is instrumental in identifying new drug targets and biological pathways tailored for developing cutting-edge cancer immunotherapies. Currently, Compugen has two proprietary product candidates in Phase 1 development:

• - COM701: A potential first-in-class anti-PVRIG antibody.
• - COM902: A promising candidate aimed at targeting TIGIT for effective treatment of solid tumors.

Moreover, Rilvegostomig, a bispecific antibody that combines PD-1 and TIGIT targeting, is in Phase 3 development under AstraZeneca's stewardship through a licensing agreement. This collaboration exemplifies Compugen's impactful partnerships in delivering advanced cancer therapies.

Another noteworthy compound in their pipeline is GS-0321 (previously known as COM503). This antibody is anticipated to be a first-in-class entity with a high affinity for IL-18 binding protein and is currently undergoing Phase 1 development, licensed to Gilead.

Compugen is not only advancing its proprietary programs but also exploring early-stage immuno-oncology research initiatives. These undertakings are geared towards amplifying anti-cancer immunity and showcasing Compugen's dedication to enhancing patient outcomes in oncology.

The company's headquarters are located in Israel, complemented by offices in San Francisco, California, reflecting its dual commitment to local innovation and global outreach. Compugen's shares are publicly traded on both Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.

This upcoming participation at the Leerink Partners Global Healthcare Conference marks another milestone in Compugen's journey, as they continue to pave the way for groundbreaking advancements in cancer treatment and immunotherapy. Enthusiasts, investors, and healthcare professionals should mark their calendars for this enriching event that promises to shed light on the future of cancer therapeutics.

For further details, media inquiries may be directed to Yvonne Naughton, Ph.D., Head of Investor Relations and Corporate Communications, at her email or via telephone. This represents not only a milestone for Compugen but a pivotal point for attendees and all stakeholders vested in the future of healthcare and cancer therapy advancements.